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The psoriatic arthritis cost evaluation study: a cost-of-illness study on
tumour necrosis factor inhibitors in psoriatic arthritis patients with
inadequate response to conventional therapy
I. Olivieri1, S. de Portu2, C. Salvarani3, A. Cauli4, E. Lubrano5, A. Spadaro6, F. Cantini7, M. S. Cutro1,
A. Mathieu4, M. Matucci-Cerinic8, N. Pappone5, L. Punzi9, R. Scarpa10 and L. G. Mantovani2,11 for the
PACE working group
Objective. To evaluate costs, benefits and cost–effectiveness of anti-TNF agents in PsA patients with inadequate response to conventional
treatment.
Methods. A total of 107 patients, from nine Italian rheumatology centres, with different forms of PsA were given anti-TNF treatment, mainly
etanercept (87%). Information on resource use, health-related quality of life, disease activity, function and laboratory values were collected at
baseline and through out the 12 months of therapy. Cost (expressed in euro 2007) and utility (measured by EuroQol) before and after anti-
TNF therapy initiation were compared in order to estimate the incremental cost per quality-adjusted life year (QALY) gained, and cost–
effectiveness acceptability curve was calculated.
Results. At the end of 12 months, there was a significant increase in direct cost due to an increase of drug cost caused by TNF inhibitors that
was only partially offset by the decrease in indirect cost. In the last 6 months of therapy, the direct cost increased by E5052, the cost for the
National Health System (NHS) by E5044 and the social cost by E4638. However, a gain of 0.12 QALY resulted in a cost per QALY gained of
E40 876 for the NHS and of E37 591 for the society. The acceptability curve showed that there would be a 97% likelihood that anti-TNF
therapy would be considered cost-effective at willingness-to-pay threshold of E60 000 per QALY gained.
Conclusion. Cost–effectiveness ratios are within the commonly accepted willingness-to-pay threshold. These results need to be confirmed in
larger samples of patients.
KEY WORDS: Psoriatic arthritis, Anti-tumour necrosis factor, Cost–effectiveness, Quality-adjusted life year.
Introduction
PsA is an inflammatory arthropathy associated with psoriasis.
It may affect the peripheral joints as well as the axial skeleton and
the peripheral entheses and is classified among the SpAs. In
the past, PsA was considered a rare and mild disease. Actually,
0.5–1% of the population may suffer from PsA since psoriasis
affects about 2–3% of the general population and PsA occurs
in one-third of the psoriatic patients [1, 2]. A frequency of 36%
was found in an Italian dermatological series of consecutive and
unselected patients with psoriasis [3]. In the last 20 yrs, evidence has
been accumulated that PsA is erosive and deforming in 40–60% of
the patients with joint damage appearing in the first year of disease
onset [4–7]. It is estimated that almost 20% of the PsA patients
develop a severe destructive disease [4–7]. Patients with PsA suffer
from reduced quality of life (QoL) and impairment of functional
status and are at greater risk of death compared with the general
population [7–9]. Therapies for PsA have been unsatisfactory until
some years ago [10]. NSAIDs are useful in relieving symptoms but
have no effect on joint damage. Local corticosteroid injections may
be of great benefit in patients with mono- or oligoarthritis but the
use of systemic corticosteroids is not supported by any evidence.
Traditional DMARDs are used in PsA to control the symptomatic
manifestations but there is no evidence that they prevent or
significantly decrease the progression rate of structural joint
damage. The anti-TNF agents (etanercept, infliximab and adali-
mumab) have opened new horizons. These drugs reduce signs and
symptoms of inflammation, improve QolL and functional status
and inhibit the progression of structural damage in peripheral
joints [11–13]. Axial disease was not assessed in these studies.
However, TNF blockers are effective in primary AS in controlling
symptoms and preventing the progression of the structural damage
in the spine [14]. These results can plausibly be extrapolated to
psoriatic spondylitis.
TNF inhibitors are very expensive and not easily available to
all patients, either depending on a national health system or
on private insurance. Illness costs in PsA were found high
even without these drugs and not much more different from
those in RA, SLE and AS [15]. Costs are also high for patients
with psoriasis alone [16]. Two strategies have been adopted to
be able to treat all PsA patients who may need anti-TNF agents.
On the one hand, evidence-based guidelines for their use have been
developed [10, 17]. On the other hand, pharmacoeconomic studies
have been promoted with the aim of demonstrating their cost–
effectiveness [18–21]. To date cost–effectiveness studies on TNF
antagonists in PsA have only been performed using data from
published international studies [19–21].
We have designed a cost evaluation study on PsA patients
with inadequate response to traditional DMARDs to be treated
with TNF blockers in clinical practice. The objective of the study
was to evaluate costs, benefits and cost–effectiveness of the class of
TNF inhibitors over 1 yr of follow-up.
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Methods
Techniques
To reach the objectives of the study, we conducted a cost-of-care
analysis, a technique used to evaluate the economic burden of a
disease [22]. Health-related Qol (HRQoL) or health state utility
was also evaluated. Cost and utility before and after anti-TNF
therapy initiation were then compared in order to estimate an
incremental cost–effectiveness ratio (cost per QALY gained). As
the measurement of costs depends on the point of view adopted
for the analysis (e.g. a hospital admission may represent a cost to
the National Health Service (NHS) or to an insurance company
but not to the patient), the study was carried out from the point of
view of the community, the largest entity that can have a point of
view, and which included the Italian third-party payer (NHS),
patients and their families.
Study cohort
Patients were consecutively enrolled during 2005 in nine Italian
tertiary referral centres after obtaining their informed consent.
Patients had to satisfy the following inclusion criteria: age older
than 18 yrs, established diagnosis of PsA and failure or intolerance
of conventional therapy.
Patients with predominant or exclusively peripheral arthritis
had not to have responded to adequate therapeutic trials of at
least two NSAIDs for at least 3 months (unless contraindicated or
not tolerated), to at least two steroid injections (in cases of mono-
or oligoarthritis) as well as to adequate therapeutic trials of at
least one of the DMARDs most commonly used in PsA (MTX,
cyclosporin, SSZ and LEF). Patients also had to have at least one
swollen joint plus at least two of the following: patient global
assessment 40mm on a 100mm visual analogue scale (VAS), 3
tender joints and ESR 28mm/1st h or CRP 15mg/l.
Patients with predominant or exclusively axial disease had to
have met the modified New York criteria [23] for the diagnosis
of AS, had to have active disease for 4 weeks with a Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) [24] 4
and had to have failed adequate trials of at least two NSAIDs for
at least 3 months, unless contraindicated or not tolerated, in
accordance with the ASAS (Assessment in Ankylosing
Spondylitis) working group recommendations for the use of
anti-TNF agents in patients with AS [25].
Patients with exclusive peripheral enthesitis or with exclusive
dactylitis had not to have responded to adequate therapeutic trials
of at least two NSAIDs for at least 3 months (unless contra-
indicated or not tolerated) and to at least two local corticosteroid
injections. They also had to have a patient global assessment
40mm on a 100mm VAS and tender enthesitis of 2 on a 0–4
Likert scale.
The subjects’s written consent was obtained according to the
declaration of Helsinki and the protocol was approved by the
institutional review boards of the participating centres. The study
was monitored by a contract research organization and was
sponsored by Wyeth Italy through an unrestricted research grant.
Observation period
Patients enrolled were studied globally for 18 months. They were
asked to provide information on resource use and HRQoL in the
preceding 6 months. In accordance with Gringeri et al. [26], 6
months seem to be a reasonable time period for a retrospective
study on patients affected by chronic intensively treated disease
such as PsA. We do not expect recall bias might impact our cost
estimates since most of the information were collected from
medical records.
Data collection. To evaluate the cost of care and the HRQoL,
patients were interviewed by means of a specially designed
structured electronic case report form (CRF; available on request
from author), which was administered to them by a physician at
each participating centre and filled in by the physician to make
sure that data were of high quality.
At the time of the enrolment visit, information was obtained on
demographic characteristics (date of birth, sex), clinical character-
istics (year from diagnosis of PsA, concomitant diseases, allergies,
complete physical examination including height and weight, vital
signs as pulse rate and blood pressure), surgical procedures,
physicians’ visits, hospitalizations, number of working days lost
by patients due to PsA, caregiver time (number of days lost)
devoted to patients’ assistance and, in general, all events leading to
resource absorption of health care and non-health care resources
during the 6 months before enrolment. This information was also
collected prospectively during the follow-up period at 6 and
12 months.
Clinical data recorded at enrolment and during the follow-up
visits included laboratory parameters (blood cell count, transa-
minases, creatininaemia, ESR mm/1st h, CRP mg/litre and RF),
68/66 tender/swollen joint count [27], number of digits with
dactylitis, Maastricht Ankylosing Spondylitis Enthesitis Score
(MASES) [28], BASDAI [24], Bath Ankylosing Spondylitis
Functional Index (BASFI) [29], occiput-to-wall distance, chest
expansion, modified Schober’s test [30], physician’s and patient’s
global assessments of pain and overall disease activity (0–10 cm
VAS), duration of morning stiffness, Psoriasis Area and Severity
Index (PASI) [31], HAQ [32], EuroQol (EQ-5D) [33, 34] and
Medical Outcome Survey Short Form-36 (SF-36) [35, 36]. At
inclusion, data on previous and current treatment with
DMARDs, analgesics, NSAIDs and corticosteroids were recorded.
During follow-up, any modifications of these drugs and of anti
TNF- treatment were registered.
Cost-of-care analysis
Costs were quantified considering the societal perspective.
Consistently, health care resources absorbed were quantified
into monetary terms in the perspective of the third-party payer,
the NHS, which in Italy is in charge of financing and providing
health care services to patients with PsA. Direct medical costs
financed by the NHS were calculated by multiplying resources
absorbed by their unit cost. They included the cost of therapies,
hospitalizations, laboratory and other diagnostic examinations,
surgery, rehabilitation procedures, physicians’ visits and any other
possible cost. Diagnosis-related group (DRG) [37] charges were
applied to estimate the cost of hospitalizations.
Cost of transport was quantified in the patients’ perspective.
Indirect costs absorbed for patients’ assistance, and caregivers’
and patients’ absenteeism were quantified in the perspective of
patients and their family, using the human capital approach.
Indirect cost attributable to reduction in or cessation of working
ability were not quantified because of the relatively short-term
observation period and the nature itself of PsA.
We report costs as follows: (i) direct NHS costs as cost related
to health care, which are financed by the NHS, i.e. all medical
costs for this sample of individuals; (ii) direct costs that include
direct NHS costs and cost of transportation; (iii) overall social
cost that includes direct costs and indirect costs as defined above.
All costs are expressed in euros from the year 2007 and are
computed as euro per patient per 6 months.
Quality of life
To evaluate HRQoL and assess health status, the widely used self-
administered questionnaire such as the EQ-5D [33, 34] and SF-36
[35, 36] were adopted.
EQ-5D is applicable to a wide range of medical conditions and
treatments and generates a health profile (EQ profile) consisting
of five domains (mobility, self-care, anxiety/depression, usual
activities and pain/discomfort) and three levels (‘no problem,’
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‘some or moderate problems,’ ‘extreme problems/impossible to
do’). A VAS (EQ-VAS) scores the overall HRQoL from 0 (the
worst imaginable health status) to 100 (the best imaginable health
status) [32, 33]. EQ-5D has been used in PsA [38]. Sokoll and
Helliwell [38] found similar scores in RA and PsA patients
matched for disease duration although RA patients had sig-
nificantly greater joint damage. The additional burden of skin
disease in PsA [39] was thought to explain these results.
Designed for use in clinical practice and research, health policy
evaluations and general population surveys, the SF-36 question-
naire is considered a standard instrument for patient-based health
care outcome assessment [35, 36]. It has been recently validated in
Italy and used in several studies ranging from epidemiological to
clinical trials [40]. Applicable to adults and adolescents, SF-36
assesses eight dimensions of HRQOL that relate to the physical
and mental components of health perception. Physical function-
ing, role-physical and bodily pain are more related to the physical
component; social functioning, role-emotional and mental health
are more related to the mental component; and energy/vitality and
general health relate to both components [34, 35]. These eight
dimensions can be grouped in two summary scores [physical
component summary (PCS) and mental component summary
(MCS)]. These global measures were estimated using standard US
algorithms [41]. To test the internal consistency of SF-36, the
Cronbach’s- was computed, with values >0.70 considered
satisfactory [42]. SF-36 has been used in several PsA therapy
trials [27].
Cost–effectiveness analysis
We used the approach described and applied by Kobelt et al. [43]
for anti-TNF therapy in RA patients. An incremental cost per
QALY gained was estimated by calculating the ratio between the
incremental cost before and after anti-TNF therapy and the
incremental utility. In order to estimate the incremental
(6 months) cost, we computed the difference between the average
cost(s) per patient in the 6 months period before anti-TNF
therapy and in the last 6 months of observation. Our choice was
motivated by the need to contrast costs and QoL data pertinent to
equivalent time periods, considering that only data for the 6
months before enrolment were available. Our analysis was
intentionally conservative; we considered data collected during
the last 6 months of follow-up in order to ensure that all patients
were being treated for at least 6 months. In order to estimate
utility, results from the EQ profile were converted to utility score,
suitable for economic evaluations, by means of an algorithm that
uses population-based (social) values [44, 45]. Because specific
conversion values for the Italian population are not available yet,
to convert our EQ profile results in EQ utility index, the algorithm
was implemented with values from the United Kingdom [46],
using the method described by Gringeri et al. [26]. QALYs gained
were estimated by computing the difference between the average
per patient utility values at enrolment, i.e. before anti-TNF
therapy and the average utility value at the end of observation, i.e.
after anti-TNF therapy initiation. This difference was then
multiplied by 0.5, as the reference unitary observation period
was 0.5 yr (i.e. 6 months)
Uncertainty due to parameter estimation was demonstrated by
calculation of the cost–effectiveness acceptability curve.
Statistical analysis
For cost-of-care analysis, we used means as central tendency
parameters, generally expressed as mean cost per patient per
month, because this parameter can be easily used to make
projections on different populations and is of easy use for policy
makers. Costs were stratified according to their category, i.e.
direct health care and indirect costs. Descriptive statistics were
applied also to define HRQOL and health status measurement
variables.
We compared direct health care costs, indirect costs and
HRQoL cost of the 6-month prior to enrolment in the study to
those related to the 6 months before the end of the study, using
paired t-test, Wilcoxon signed-rank test or Mc Nemar test
depending on the shape and type of the distribution of the
variable to be tested. P-values < 0.05 were considered statistically
significant. All analyses were performed using SPSS versions 14.0
and 15.0 software (SPSS, Chicago, IL, USA).
Results
A total of 107 patients with PsA met the inclusion criteria in the
enrolment period extending from January to December 2005.
Ninety-three out of the 107 received etanercept, 15 infliximab and
8 adalimumab. During the follow-up period, 10 patients were
switched from one to another TNF antagonist for diverse reasons.
The reason for the repartition of our patients among the three
available TNF inhibitors was due to the different times of their
formal introduction in Italy. Etanercept was allowed for PsA in
2004 and the two antibodies during 2005. At the end of
observation seven (6.5%) patients had stopped anti-TNF therapy
for diverse reasons. In order to avoid bias in favour of anti-TNF
therapy in the estimate of effectiveness and QALY, they were
included in the analysis. The baseline characteristics of the
patients are shown in Table 1. The majority of patients (87) had
a predominant or exclusive peripheral arthritis, 19 had predomi-
nant or exclusively axial involvement and only 1 had exclusive
peripheral enthesitis. Table 2 shows the cost per patient for the
6 months preceding the beginning of the observation period. The
mean overall direct and indirect costs were E942.87 and E576.30,
respectively, with the cost for drugs accounting for E630.85.
Social costs were E1519.17: 41.5% attributable to cost of drugs,
37.9% attributable to indirect cost and 11.0% attributable to
hospitalization, while costs for the NHS were E883.09.
Table 3 shows the improvement of the most important clinical
variables at the end of the 12 months of follow-up. There was a
significant improvement of levels of pain and activity, numbers of
swollen and tender joints, and MASES, BASDAI, BASFI, HAQ
and PASI. The direct cost increased by E5052.34, the cost for the
NHS by E5044.21 and the social cost by E4638.72 (value referring
to 6 months) (Table 4). There was also a significant increase of
direct cost, cost for the NHS and social cost caused by an increase
of drug cost due to TNF inhibitors. This increase was partially
offset by the decrease in overall indirect cost. At the end of the
12-month observation there was a significant increase by 19.4
points in the EQ-5D VAS with a gain in utility of 0.25.
The results of SF-36 are shown in Fig. 1. Low levels were
detected at baseline in all domains with the lowest values in the
physical-role and emotional-role domains and the highest in
energy/vitality and mental health domains. The mean value of
QoL measured by EQ-5D VAS was 47.12 with a utility of 0.38.
Figure 2 shows the EQ-5D profile results. At baseline, two-thirds
or more of patients reported ‘some/moderate problems’ in all five
domains. The percentage of patients with ‘extreme problems/
impossible to do’ ranged between 1% in the mobility domain and
26% in pain and discomfort domain. QoL improved as demon-
strated by the significantly higher values in both SF-36 (Fig. 1)
and EQ-5D profile (Fig. 2). In the first (Fig. 1), there was a
significant improvement in all domains except in the energy/
vitality and in mental health domains. In the second (Fig. 2),
the proportion of patients with ‘no problems’ increased in all five
domains.
In the last 6 months of follow-up, there were incremental costs
compared with the 6 months preceding the beginning of the
observation (Table 5). However, the utility gain of 0.25 gave a
QALY gain of 0.12 resulting in a cost per QALY gained of
E40 876.90 for the NHS and of E37 591.01 for the society. The
cost–effectiveness acceptability curve (Fig. 3) suggests that if
decision makers’ willingness to pay per QALY was E45 000 then
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anti-TNF treatment would be cost effective in 82% of the cases and
that this would be increased to 97% if the threshold for willingness
to pay was raised to E60 000.
Discussion
To the best of our knowledge ours is the first pharmacoeconomic
study on anti-TNF- drugs in PsA in clinical practice.
The previous published studies dealt with data from published
international trials [19–21]. Over 10 yrs of treatment, Bansback
et al. [19] found a cost of about £30 000 per QALY gained by using
etanercept as compared with LEF or combination MTX and
cyclosporin. Woolacott et al. [20] found an incremental cost
per QALY gained of etanercept compared with no active therapy
of £14 818–£49 374 in a systematic review and economic evaluation
on etanercept and infliximab. Eandi and Salvarani [21] compared
cost/effectiveness and cost/utility of etanercept, infliximab
and adalimumab examining data obtained from three Phase III
trials.
In our study in clinical practice, cost–effectiveness ratios
between therapy with TNF blockers and traditional therapy for
PsA were calculated based on the change of costs and utilities
from baseline, rather than on a comparison among different
treatments. This is not a customary technique in economic
evaluation, but is similar to that used by Kobelt et al. [43] to
evaluate cost–effectiveness of TNF inhibitors in the treatment of
RA in clinical practice. We chose this strategy for two reasons.
The first was the superiority of TNF antagonists to traditional
DMARDs in controlling signs and symptoms and inhibiting the
progression of structural damage of PsA [11–13]. Accordingly, we
wanted to offer a more effective therapy to our patients. With this
view, aimed to start this new therapy earlier in the course of
disease, we enrolled patients with peripheral arthritis who had
failed one DMARD and not two as in the recommendations of the
Italian Society of Rheumatology for beginning TNF inhibitors in
patients with predominant peripheral arthritis [17]. These recom-
mendations, along with others for initiating these drugs in the
rheumatic diseases in which they are allowed, are deeply
conditioned by the high cost of anti-TNF treatment. The second
reason was our interest in the current study of all forms of PsA
and not on individual forms (axial, peripheral arthritis, peripheral
enthesitis and dactylitis) separately. Today, there are different
pharmacological options for peripheral arthritis. On the contrary,
pharmacological therapy for psoriatic spondylitis, similarly to
primary AS, is based on NSAIDs with DMARDs having no
TABLE 1. Baseline patient characteristics
Mean or frequency S.D. 95% CI
Lower, Upper
Total number of patients 107 –
Patients with predominant peripheral arthritis, n (%) 87 (81.3) –
Patients with predominant axial involvement, n (%) 19 (18.8) –
Patients with exclusive peripheral enthesitis, n (%) 1 (0.9) –
Male patients, n (%) 51 (47.7) –
Age (yrs) 49.68 11.7 47.47, 51.90
Years since diagnosis of PsA 7.32 7.4 2.89, 8.28
Patient’s assessment of pain (0–100) 62.83 21.10 58.77, 66.90
Patient’s assessment of disease activity (0–100) 63.51 17.25 60.18, 66.86
Physician’s assessment of disease activity (0–100) 60.15 13.33 57.57, 62.73
Swollen joint count (0–66) 7.60 6.39 6.37, 8.82
Tender joint count (0–68) 16.97 11.8 14.71, 19.24
MASES index (0–13) 3.65 3.76
BASDAI (0–10)
All patients 5.95 1.82 5.60, 6.30
Patients with axial involvement 6.4 1.72 5.57, 7.24
Patients with peripheral involvement 5.86 1.84 5.48, 6.26
BASFI (0–100)
All patients 43.37 24.49 38.68, 48.07
Patients with axial involvement 49.94 22.29 39.19, 60.69
Patients with peripheral involvement 41.87 24.96 36.55, 47.19
PASI (0–72) 5.04 7.29 3.64, 6.44
HAQ (0–3) 1.14 0.57 1.03, 1.25
Therapies in the 6 months before enrolment, n (%)
LEF 12 (11.2)
MTX 53 (49.5)
SSZ 15 (14.0)
Glucorticoids 46 (43.0)
NSAIDs 42 (39.3)
COXIBx 27 (25.2)
No DMARDs 37 (34.6)
TABLE 3. Changes (improvement or reduction) in patient clinical characteristics at
the end of the study in comparison with baseline value
Variable Mean (S.D.) 95% CI t-test P-value
Lower, Upper
Patient’s assessment of pain 31.18 (27.56) 25.88, 36.49 11.65 <0.0001
Physician’s assessment
of disease activity
33.83 (19.60) 30.04, 37.63 17.69 <0.0001
Patient’s assessment
of disease activity
31.18 (24.48) 26.44, 35.91 13.05 <0.0001
Swollen joint count 6.33 (5.94) 5.10, 7.47 11.04 <0.0001
Tender joint count 9.00 (11.16) 6.86, 11.13 8.34 <0.0001
MASES 1.486 (2.96) 0.918, 2.05 5.18 <0.0001
BASDAI 2.72 (2.39) 2.26, 3.18 11.81 <0.0001
BASFI 17.72 (27.89) 12.38, 23.07 6.57 <0.0001
HAQ 0.48 (0.66) 0.35, 0.62 7.19 <0.0001
PASI 3.75 (7.03) 2.40, 5.10 5.50 <0.0001
TABLE 2. Cost of care of patients in the 6 months before the beginning of the study
Mean S.D. 95% CI
Lower, Upper
Overall direct cost 942.87 1156.11 721.29, 1164.46
Cost of drugs 630.85 963.20 446.24, 815.47
Cost of hospitalization 167.50 627.389 47.25, 287.75
Cost to the NHS 883.09 1148.65 662.94, 1103.26
Indirect cost 576.30 1565.11 276.33, 876.28
Social cost 1519.17 1945.16 1146.36, 1891.99
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evidence-based role. The ASAS/EULAR recommendations for
the management of primary AS state that patients failing NSAID
therapy should be treated with TNF blockers without trying or
combining SSZ or MTX [25]. Therefore patients with predomi-
nant axial involvement did not have any other possible therapeutic
option other than TNF inhibitors.
With the perspective of evaluating the entire clinical spectrum
of the disease we chose unique principal instruments for
measuring function and disease activity. BASFI and BASDAI,
designed for measuring disease activity and function in primary
AS, have been shown to have good internal consistency on both
peripheral and axial PsA disease [47]. Similarly, both HAQ and its
modified version for spondyloarthritides (HAQ-S) have been
shown to be valid measures for function in PsA patients with
peripheral and/or axial disease [48].
The patients of the present study had low EQ-5D and SF-36
scores at baseline. Utility values appeared to be lower than the
ones that could have been expected from disease activity and
function values. This probably reflects the negative effect of
psoriasis on HRQoL [38] even if the baseline PASI score was only
5. Severe skin disease may cause problems with self-esteem and
this may be reflect on the score of anxiety and depression subscale
of the EuroQoL-5D. In addition, involvement of hands and
genital areas may affect activities of self-care and hygiene.
The cost for the society of PsA treatment in the 6 months before
the beginning of the study was E1519.17, different from that
found by Huscher et al. [15] in German PsA patients. They found
a total cost per year of E11 075 considering different types of
costs, which is likely to explain the differences. Indeed, when
comparable costs (i.e. direct health care costs) are considered, our
estimate of pre-treatment cost of 950 euros per 6 months is in
line with the estimate of about 3100 euros per year, taking into
account that our patients have shorter disease duration and higher
functional status than those studied by Huscher et al.
At the end of 12 months of observation, there was a significant
increase in the vast majority of SF-36 and EQ-5D domain scores
resulting in a gain in EQ-5D utility of 0.25. This was due to the
significant improvement of PsA disease activity, function status
and psoriasis. The cost for the society and the NHS increased
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FIG. 3. Cost–effectiveness acceptability curve.
TABLE 4. Difference in overall cost of care (E) and its components between baseline and the end of follow-up
Variable Mean (S.D.) 95% CI t-test P-value
Lower, Upper
Increase in overall direct cost 5052.34 (2716.61) 4531.66, 5573.02 19.238 <0.0001
Increase in cost of drugs 5189.97 (2686.59) 4675.04, 5704.89 19.983 <0.0001
Decrease in cost of hospitalization 142.63 (667.16) 14.76, 270.49 2.21 0.029
Increase in overall direct cost to NHS 5044.21 (2739.56) 4519.12, 5569.27 19.046 <0.0001
Decrease in overall indirect cost 413.34 (1574.09) 715.32, 111.92 2.71 0.007
Increase in overall social cost 4638.73 (3087.08) 4047.03, 5230.40 15.543 <0.0001
Increase in EQ-5D VAS 19.40 (25.00) 14.59, 24.22 7.99 <0.0001
Increase in EQ-5D utility 0.25 (0.31) 0.18, 0.30 8.06 <0.0001
TABLE 5. Incremental cost–effectiveness ratios of anti-TNF- therapy related to
comparable periods before and after anti-TNF- therapy (6 months before
enrolment compared with the last 6 months of the study
Variable
Incremental cost
(E) (6 months)
Utility gain
(utility at final  utility
at initial observations)
QALY gain
(6 months)
Cost/QALY
(E)
Direct cost 5052.34 0.25 0.12 40 942.78
NHS cost 5044.21 0.25 0.12 40 876.90
Social cost 4638.73 0.25 0.12 37 591.01
Data are rounded to two significant digits.
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significantly as a consequence of the high costs of TNF inhibitors.
This increase was only partially offset by the reduction of the
indirect costs. On considering the last 6 months of the study, social
costs increased by E4638.73, cost for the NHS increased by
5044.21 and direct cost increased by E5052.34. However, the
utility gain of 0.12 gave a cost for QALY gained of E37 591.01,
E40 876.90 and E40 942.78, respectively. The magnitude of cost
per QALY similar to that of our study has already been observed
by Kobelt and colleagues [43] in RA patients. Similar to what has
been observed in RA patients treated with anti-TNF agents,
models that examined PsA treatment had previously estimated
that biological therapy would become cost effective only in the
long term [19].
The choice of comparing the 6 months period before enrolment
and the last 6 months of observation was motivated by the need to
contrast, within the same patient, periods of time in which the
patient was exposed vs not exposed to biological therapy. The
unexposed period was the one before enrolment whereas the last
6 month of observation (6–12 months) was the only period
in which all the patients had been exposed to biological therapy
at least once.
In fact, administrative barriers (high cost of drugs and limited
pharmaceutical budget), may cause delays in the initiation
of biological therapy even if this was indicated at enrolment.
Consequently, some patients did not actually receive therapy
for this reason therapy before the sixth month of follow-up.
In turn, other patients had already stopped therapy (due to side-
effects or lack of efficacy) by month 12.
Therefore, our costs and utilities estimates referring to the last 6
months actually, incorporate and factor in, real word events like
therapeutic failure, induction periods, therapeutic switch, etc.
Our results with PsA are also consistent with the observation in
an RA setting [43] that the anti-TNF therapy is cost effective even
in the short term, and that this is mainly attributable to the
dramatic improvement in functional status and, consequently in
quality of life. The importance of this observation is related to the
fact that public decisions makers are keen to have a short- or
mid-term time horizon rather than a long-term one. In this view,
anti-TNF therapy seems to generate its ‘pay-offs’ in term of
effectiveness and cost–effectiveness rather soon after initiation,
thus reducing the usual time gap between an investment in health
care and its returns in terms of health. In particular, our results are
mostly based on patients treated with etanercept accounting for
87% of the study population.
Anyway, it should be considered that cost–effectiveness ratios
do not themselves provide information about whether the
treatment is a cost effective use of resources. This decision
depends on the perspective of the health care payer. One approach
often used to assess the value of a treatment is to compare its cost–
effectiveness ratio with ratios obtained with treatments in other
fields. Whether a more effective yet more expensive treatment is
cost-effective depends on the health payer’s willingness to pay for
additional benefits. The value of this threshold is difficult to
quantify. In the United Kingdom, recent recommendations for the
treatment by the National Institute of Clinical Excellence (NICE)
seems to suggest a threshold of about £30 000 (E45 000) per
QALY [49]. In the last few years, a threshold of E60 000 per
QALY gained has been proposed for Italy [50]. Using these
thresholds, anti-TNF treatment in our cohort appears acceptable
already in the first year of treatment. In fact, taking E60 000 per
QALY as the maximum acceptable cost–effectiveness ratio in
Italy, which is broadly in line with decisions from the NICE [49],
the probability of being cost-effective in 6 months is 97%.
The quality of the collecting data is very important in all health
economic studies. In observational and clinical practice-based
studies such as ours, there is always the possibility of compliance
problems. To avoid these, patients and physicians were particu-
larly motivated and made conscious of the importance of
collecting information and data were gathered by the physicians.
However, this motivation should not have introduced significant
bias in favour of the cost–effectiveness of anti-TNF by magnifying
the utility benefits. We also used electronic tools to minimize
missing data and to improve the precision of data collection. In
addition, the study was monitored by a contract research
organization to guarantee quality.
In conclusion, our study suggests that TNF antagonists provide
‘value’ and ‘value for money’ in the treatment of PsA in clinical
practice. However, our results (mainly valid for etanercept) should
be confirmed by studies in larger numbers of patients with
different disease duration, severity and functional disability.
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